[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634021":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":30,"locations":37,"responsibleParty":60,"collaborators":63,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":10,"maxAge":10,"enrollmentInfo":86,"targetDuration":89,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":106,"whyStopped":10,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"London School of Hygiene and Tropical Medicine","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"MOVIE",null,"Confirmed Mpox cases",{"label":13,"type":10,"description":14,"interventionNames":10},"TRACE","Contacts of a MOVIE case",{"label":16,"type":10,"description":17,"interventionNames":10},"VE","Confirmed Mpox cases and their contacts",[19,22,25,28],{"name":20,"affiliation":5,"role":21},"Edward M Choi, PhD","PRINCIPAL_INVESTIGATOR",{"name":23,"affiliation":5,"role":24},"Michael E Marks, PhD","STUDY_CHAIR",{"name":26,"affiliation":27,"role":24},"Oriol Mitjà, PhD","Fundación FLS de lucha contra el sida las enfermedades infecciosas y la promoción de la salud y la ciencia, Spain",{"name":29,"affiliation":5,"role":21},"Deborah Watson-Jones, PhD",[31,35],{"name":20,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","+44 20 7636 8636","edward.choi@lshtm.ac.uk",{"name":29,"role":32,"phone":33,"phoneExt":10,"email":36},"deborah.watson-jones@lshtm.ac.uk",[38],{"facility":39,"status":10,"city":40,"state":10,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Centre National de Formation et de Recherche en Sante Rurale de Maferinyah","Conakry","Guinea","GN",{"type":44,"coordinates":45},"Point",[46,47],-13.67729,9.53795,{"lat":47,"lon":46},[50,54,56,58],{"name":51,"role":32,"phone":52,"phoneExt":10,"email":53},"Abdoul H Beavogui, PhD","+224 628 04 53 52","bea@maferinyah.org",{"name":55,"role":21,"phone":10,"phoneExt":10,"email":10},"Abdoul H Beavogui, MD, PhD",{"name":57,"role":21,"phone":10,"phoneExt":10,"email":10},"Sory Conde, MD, MPH",{"name":59,"role":21,"phone":10,"phoneExt":10,"email":10},"Mahamoud Sama Cherif, MD, PhD",{"type":21,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Edward Choi","Assistant Professor",[64,66,69,71,74],{"name":65,"class":6},"University of Glasgow",{"name":67,"class":68},"Centre National de Formation et de Recherche en Sante Rurale","OTHER_GOV",{"name":70,"class":6},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"name":72,"class":73},"Agence Nationale de Sécurité Sanitaire de Guinée (ANSS)","UNKNOWN",{"name":75,"class":73},"Institut National de la Santé Publique de Guinée (INSP)","100634021","understanding-mpxv-viral-clearance-transmission-dynamics-and-mpox-vaccine-effectiveness-in-west-africa--guinea-100634021",false,"NCT07534267","Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea","Understanding MPXV Viral Clearance in Mpox Patients and Evaluating Transmission Dynamics of MPXV and Mpox Vaccine Effectiveness in West Africa : The Republic of Guinea","MOVIE-TRACE-WA","Inclusion Criteria:\n\n1. MOVIE-West Africa\n\n   * Individuals of any sex and age.\n   * Confirmed Mpox cases who tested positive for MPXV by PCR.\n   * Symptom onset within the 10 days prior to the baseline assessment.\n   * Willingness and ability to comply with study procedures and attend scheduled follow-up visits for up to two months.\n   * Availability for follow-up throughout the study period.\n   * Provision of written informed consent by the participant, or consent by a legally authorized representative for minors or individuals unable to provide it themselves.\n   * Assent obtained from children aged 12 to 17 years.\n   * For individuals who cannot read or write, witnessed consent will be obtained.\n2. TRACE-West Africa\n\n   * Individuals who have had close physical contact with a PCR-confirmed Mpox case within 14 days from the onset of symptoms in the index case.\n   * Close physical contact is defined as being within 2 meters of an infected person-particularly in enclosed spaces-for at least 5 minutes (based on CDC's 2-meter rule for droplet transmission).\n   * Willingness and ability to comply with the study protocol and attend scheduled follow-up assessments.\n   * Provision of written informed consent by the participant, or consent by a legally authorized representative for individuals unable to provide it themselves.\n   * Assent obtained from children aged 12 to 17 years.\n   * For individuals who cannot read or write, witnessed consent will be obtained.\n3. VE-West Africa\n\n   * The inclusion criteria for Mpox cases in VE-West Africa are same as those in MOVIE-West Africa.\n   * The inclusion criteria for contacts of Mpox cases in VE-West Africa are as follows.\n   * Individuals who have had close physical contact with a PCR-confirmed Mpox case within 14 days from the onset of symptoms in the index case.\n   * Close physical contact is defined as being within 2 meters of an infected person-particularly in enclosed spaces-for at least 5 minutes (based on CDC's 2-meter rule for droplet transmission).\n   * Individuals living, working or studying in a community where mpox vaccination is being offered.\n   * Willingness and ability to comply with the study protocol and attend scheduled follow-up assessments.\n   * Provision of written informed consent by the participant, or consent by a legally authorized representative for individuals unable to provide it themselves.\n   * Assent obtained from children aged 12 to 17 years.\n   * For individuals who cannot read or write, witnessed consent will be obtained.\n\nExclusion Criteria:\n\n(1) MOVIE-West Africa\n\n* Cases of severe Mpox requiring hospitalization.\n* Individuals with a confirmed alternative diagnosis explaining their illness.\n\n  (3) VE-West Africa\n* The exclusion criteria for Mpox cases in VE-West Africa are as follows.\n* Cases of severe Mpox requiring hospitalization.\n* Individuals with a confirmed alternative diagnosis explaining their illness.",true,"ALL",{"count":87,"type":88},992,"ESTIMATED","56 Days","OBSERVATIONAL","This study has three primary objectives to address the public health challenges of the Mpox outbreak in Guinea, West Africa. Objective 1 (MOVIE-West Africa) focuses on understanding the kinetics of Monkeypox virus (MPXV) elimination from the human body in Mpox cases. Objective 2 (TRACE-West Africa) aims to determine the MPXV transmission dynamics between Mpox cases and their contacts. Objective 3 (VE-West Africa) examines the vaccine effectiveness of the MVA-BN vaccine in protection against MPXV infection and Mpox disease.",[93,94],"Mpox (Monkeypox)","Monkeypox",[96,94,97,98,99,100,101,41,102,103,104,105],"Mpox","MPXV","transmission dynamics","vaccine effectiveness","secondary attack rate","MVA-BN","sub-Saharan Africa","West Africa","MOVIE-TRACE","viral clearance","NOT_YET_RECRUITING","2026-04-10",{"date":109,"type":110},"2026-04-16","ACTUAL",{"date":109,"type":88},{"date":113,"type":88},"2027-08",{"name":5,"class":6},1]